Abstract | BACKGROUND: METHODS: Expression of the IGF system in 24 carcinomas obtained from total prostatectomies after hormone therapy was examined. Expression levels of mRNA of each component of the IGF system were analyzed by quantitative reverse transcription-polymerase chain reaction procedures and compared with clinicopathologic parameters. RESULTS: CONCLUSIONS:
|
Authors | K Mita, M Nakahara, T Usui |
Journal | International journal of urology : official journal of the Japanese Urological Association
(Int J Urol)
Vol. 7
Issue 9
Pg. 321-9
(Sep 2000)
ISSN: 0919-8172 [Print] Australia |
PMID | 11020056
(Publication Type: Journal Article)
|
Chemical References |
- Antineoplastic Agents, Hormonal
- DNA Primers
- Insulin-Like Growth Factor Binding Proteins
- RNA, Messenger
- Receptor, IGF Type 2
- Gonadotropin-Releasing Hormone
- Insulin-Like Growth Factor I
- Insulin-Like Growth Factor II
- Receptor, IGF Type 1
- Prostate-Specific Antigen
|
Topics |
- Aged
- Antineoplastic Agents, Hormonal
(administration & dosage)
- DNA Primers
- Gene Expression Regulation, Neoplastic
- Gonadotropin-Releasing Hormone
(agonists)
- Humans
- Insulin-Like Growth Factor Binding Proteins
(genetics)
- Insulin-Like Growth Factor I
(genetics)
- Insulin-Like Growth Factor II
(genetics)
- Lymphatic Metastasis
- Male
- Middle Aged
- Predictive Value of Tests
- Prognosis
- Prostate-Specific Antigen
(blood)
- Prostatic Neoplasms
(drug therapy, genetics, physiopathology)
- RNA, Messenger
(analysis)
- Receptor, IGF Type 1
(genetics)
- Receptor, IGF Type 2
(genetics)
|